Embryonic stem cell-based therapies exhibit great potential for the treatment of Parkinson's disease (PD) because they can significantly rescue PD-like behaviors. However, whether the transplanted cells themselves release dopamine in vivo remains elusive. We and others have recently induced human embryonic stem cells into primitive neural stem cells (pNSCs) that are self-renewable for massive/transplantable production and can efficiently differentiate into dopaminelike neurons (pNSC-DAn) in culture. Here, we showed that after the striatal transplantation of pNSC-DAn, (i) pNSC-DAn retained tyrosine hydroxylase expression and reduced PD-like asymmetric rotation; (ii) depolarization-evoked dopamine release and reuptake were significantly rescued in the striatum both in vitro (brain slices) and in vivo, as determined jointly by microdialysis-based HPLC and electrochemical carbon fiber electrodes; and (iii) the rescued dopamine was released directly from the grafted pNSC-DAn (and not from injured original cells). Thus, pNSC-DAn grafts release and reuptake dopamine in the striatum in vivo and alleviate PD symptoms in rats, providing proofof-concept for human clinical translation.
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dopamine | Parkinson's disease | striatum in vivo | neural stem cells | CFE P arkinson's disease (PD) is a chronic progressive neurodegenerative disorder characterized by the specific loss of dopaminergic neurons in the substantia nigra pars compacta and their projecting axons, resulting in loss of dopamine (DA) release in the striatum (1) . During the last two decades, cell-replacement therapy has proven, at least experimentally, to be a potential treatment for PD patients (2) (3) (4) (5) (6) (7) and in animal models (8) (9) (10) (11) (12) (13) (14) (15) . The basic principle of cell therapy is to restore the DA release by transplanting new DA-like cells. Until recently, obtaining enough transplantable cells was a major bottleneck in the practicability of cell therapy for PD. One possible source is embryonic stem cells (ESCs), which can develop infinitely into self-renewable pluripotent cells with the potential to generate any type of cell, including DA neurons (DAns) (16, 17) .
Recently, several groups including us have introduced rapid and efficient ways to generate primitive neural stem cells (pNSCs) from human ESCs using small-molecule inhibitors under chemically defined conditions (12, 18, 19) . These cells are nonpolarized neuroepithelia and retain plasticity upon treatment with neuronal developmental morphogens. Importantly, pNSCs differentiate into DAns (pNSC-DAn) with high efficiency (∼65%) after patterning by sonic hedgehog (SHH) and fibroblast growth factor 8 (FGF8) in vitro, providing an immediate and renewable source of DAns for PD treatment. Importantly, the striatal transplantation of human ESC-derived DA-like neurons, including pNSC-DAn, are able to relieve the motor defects in a PD rat model (11-13, 15, 19-23) . Before attempting clinical translation of pNSC-DAn, however, there are two fundamental open questions. (i) Can pNSC-DAn functionally restore the striatal DA levels in vivo?
(ii) What cells release the restored DA, pNSC-DAn themselves or resident neurons/cells repaired by the transplants?
Regarding question 1, a recent study using nafion-coated carbon fiber electrodes (CFEs) reported that the amperometric current is rescued in vivo by ESC (pNSC-DAn-like) therapy (19) . Both norepinephrine (NE) and serotonin are present in the striatum (24, 25) . However, CFE amperometry/chronoamperometry alone cannot distinguish DA from other monoamines in vivo, such as NE and serotonin ( Fig. S1 ) (see also refs. [26] [27] [28] . Considering that the compounds released from grafted ESC-derived cells are unknown, the work of Kirkeby et al. was unable to determine whether DA or other monoamines are responsible for the restored amperometric signal. Thus, the key question of whether pNSCDAn can rescue DA release needs to be reexamined for the identity of the restored amperometric signal in vivo.
Regarding question 2, many studies have proposed that DA is probably released from the grafted cells (8, 12, 13, 20) , whereas others have proposed that the grafted stem cells might restore striatal DA levels by rescuing injured original cells (29, 30) . Thus, whether the grafted cells are actually capable of synthesizing and
Significance
With a combination of HPLC and carbon fiber electrodes, we demonstrate that grafted neural stem cells directly release dopamine in the damaged striatum in vivo and partially rescue a Parkinson's disease (PD) model. (i) Primitive neural stem celldopamine-like neuron (pNSC-DAn) retained tyrosine hydroxylase expression and reduced the PD-like asymmetric rotation; (ii) depolarization-evoked dopamine release and reuptake were significantly rescued in striatum in vitro (brain slices) and in vivo, as determined jointly by microdialysis-based HPLC and electrochemical micro-carbon fiber electrodes; and (iii) the rescued dopamine was released directly from the grafted pNSC-DAn (not from the injured original cells). Thus, pNSC-DAn grafts release and reuptake dopamine in the striatum in vivo and alleviate PD symptoms in rats, providing proof-of-concept for human clinical translation.
releasing DA in vivo must be investigated to determine the future cellular targets (residual cells versus pNSC-DAn) of treatment.
To address these two mechanistic questions, advanced in vivo methods of DA identification and DA recording at high spatiotemporal resolution are required. Currently, microdialysisbased HPLC (HPLC) (31) (32) (33) and CFE amperometric recordings (34, 35) have been used independently by different laboratories to assess evoked DA release from the striatum in vivo. The major advantage of microdialysis-based HPLC is to identify the substances secreted in the cell-grafted striatum (33) , but its spatiotemporal resolution is too low to distinguish the DA release site (residual cells or pNSC-DAn). In contrast, the major advantage of CFE-based amperometry is its very high temporal (ms) and spatial (μm) resolution, making it possible to distinguish the DA release site (residual cells or pNSC-DAn) in cultured cells, brain slices, and in vivo (34) (35) (36) (37) (38) (39) , but it is unable to distinguish between low-level endogenous oxidizable substances (DA versus serotonin and NE) in vivo.
In the present study, we developed a challenging experimental paradigm of combining the two in vivo methods, microdialysisbased HPLC and CFE amperometry, to identify the evoked substance as DA and its release site as pNSC-DAn in the striatum of PD rats.
Results
DA Release from Cultured pNSC-DAn. As described previously, we differentiated human ESCs into pNSCs using small-molecule inhibitors that inhibit glycogen synthase kinase 3 and the transforming growth factor beta (TGF-β) and Notch signaling pathways. These pNSCs resemble nonpolarized neuroepithelia and remain stably renewable in vitro. Importantly, they retain plasticity and can generate midbrain DA-like neurons or hindbrain motor neurons with high efficiency after being patterned with the appropriate morphogens (18) (see also refs. 12, 19). After treatment with SHH and FGF8, pNSCs consistently produced ∼65% tyrosine hydroxylase (TH)-positive neurons, and most of the differentiated cells also expressed the mature neuron marker microtubule-associated protein 2 (MAP2) and the midbrain marker nuclear receptor related 1 protein (Nurr1) (Fig. 1A) , indicating that the pNSCs had transformed into DA-like neurons (pNSC-DAn). Considering the potential application of pNSC-DAn in cell-replacement therapy, it was important to determine whether they were functional DAreleasing cells. HPLC analysis demonstrated the release of DA from pNSC-DAn in response to stimulation with 50 mM K + in Krebs-Ringer solution ( Fig. 1 B and C) . Consistently, 3,4-dihydroxyphenylacetic acid (DOPAC), a metabolite of DA, was also detected during the depolarizing stimulation ( Fig. 1 B and C) . To quantify the DA release from these cells, correlation curves between the concentrations of standard samples (DA and DOPAC) and their corresponding peak areas in HPLC were calculated. The calibration formulas of the analyte were as follows: y = 0.60x − 0.0012 (r 2 = 0.999) for DA, and y = 0.53x − 0.0022 (r 2 = 0.999) for DOPAC (y, peak area; x, analyte concentration in μM; Fig. S2D ). The concentrations of DA and DOPAC from differentiated pNSC-DAn increased in the presence of 50 mM K + (Fig. 1C ). In contrast, NE was not detected after stimulation with 50 mM K + (Fig. S3) , excluding the possibility of NE release from these THpositive pNSC-DAns.
Transplantation of pNSC-DAn Relieves the Asymmetric Rotation
Defect in PD Rats. To determine whether the pNSC-DAns relieve Parkinsonian syndrome, we transplanted these cells into the ipsilateral striatum at week 4 after unilateral administration of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB). To identify the transplanted cells, these pNSCs were infected with lentivirus carrying GFP under the control of the EF-1α promoter, as previously reported ( Fig. 2A) (18) . Most of the GFP-labeled grafted cells survived and remained TH-positive 1 wk after transplantation (Fig. 2B) . Importantly, the surviving cells still exhibited TH and MAP2 staining in the grafted area 16 wk after transplantation (Fig. 2C and Fig. S4 ). Further characterization also revealed the expression of DA D2 receptor, aldehyde dehydrogenase 1 (ALDH1A1), and vesicular monoamine transporter-2 (VMAT2) in grafted cells, indicating the persistence of mature DAns in vivo (Fig. S5) . The apomorphine-induced asymmetric rotation was assessed every 4 wk from the day of transplantation until 16 wk (Fig. 2D) . Note, compared with the PBS-injected PD rats (PD-PBS), animals with pNSC-DAn (PD-DAn) showed a significant and progressive reduction in contralateral rotations over time (Fig. 2D , Lower Left). Compared with that before transplantation, there was a gradual and significant recovery in rotation in PD-DAn rats during the 16 wk after transplantation (Fig. 2D , Lower Right).
Grafted Cells Restore Stimulus-Induced DA Overflow in PD Striatum in Vivo. The concentration of DA and its metabolites in PD-PBS, PD-DAn, and intact striatum were analyzed for evoked DA release in vivo by microdialysis-based HPLC, which provided unequivocal chemical verification of depolarization-dependent electrochemical signals including DA rather than NE and serotonin. In the intact striatum, the DA signal increased significantly with 70-mM K + stimulation, which was consistent with the stimulus dependence of DA secretion in the striatum (Fig. S2) . Compared with that in the control side, DA and its metabolites DOPAC and homovanillic acid (HVA) decreased remarkably in the PD-PBS striatum (Fig. 3) . The diminished DA signal in the PD striatum was partially rescued by the pNSC-DAn grafts (Fig. 3) (PD-DAn, 0.011 ± 0.004 μM; PD-PBS, 0.002 ± 0.0002 μM; P < 0.05). After pNSC-DAn transplantation, the DA level in the PD-DAn striatum recovered to ∼6% of that in the intact side (Fig. 3) . These results confirmed that the grafted pNSC-DAn relieved the rotation defect probably due to the increased DA level in the striatum. Grafted Neurons Partially Rescue DA Release in Striatal Slices. DA and its metabolites are easily oxidizable and can be detected by both HPLC (32, 33) , which can identify substances (Fig. S2) , and CFE amperometry (34, 35, 37, 38, 40) , which has extremely high spatial and temporal resolution. Because the evoked release of DA and its metabolites had been confirmed by HPLC (Fig. 3) , we performed amperometric recordings in striatal slices to determine whether the increased DA level in the striatum was due to its release from grafted pNSC-DAn. Because the pNSCs expressed GFP, the grafted neurons and fibers were clearly visible under a fluorescence microscope (Fig. 4A, Left) , and CFEs were used to record DA release in the grafted areas (Fig. 4A, Right) . Local application of 70-mM K + induced repeatable DA signals represented by the amperometric current I amp , both in intact and pNSC-DAn-grafted striatal slices (Fig. S6) . In contrast, the depolarization-evoked DA overflow was diminished in striatal slices from the lesioned side of PD-PBS rats (Fig. 4 B and D 
However, the evoked DA overflow was partially restored in PD-DAn slices (Fig. 4 B and D) (6.1 ± 1.1 pA; PD-DAn, 26.1 ± 7.4 pA, P < 0.01), and occurred exclusively in the grafted regions (Fig. 4 C and E) (outside graft, 2.8 ± 0.8 pA; inside graft, 25.6 ± 6.3 pA; P < 0.01). The specificity of DA release in the GFPpositive area was consistent with the observation that the grafted pNSC-DAn remained TH-positive and that the TH-positive staining was mainly detected in GFP-positive cells and processes (Fig. 2 A-C and Fig. S4) . Combined with the absence of TH staining in the striatum on the lesioned side (Fig. S7) and that the differentiated pNSCs secreted DA in vitro, these findings demonstrated that the increased DA signal in the striatum is due to direct release from the grafted pNSC-DAn.
Grafted Neurons Partially Rescue DA Release in PD Rats in Vivo. To further assess the potential therapeutic effect of grafted cells, we performed in vivo amperometric recordings in anesthetized PDDAn rats. Electrical stimulation of the DA fibers in the MFB is commonly used to evoke DA release in the striatum in vivo (34) . However, the original MFB and striatal DA terminals on the lesioned side in PD-DAn rats were damaged, so we designed a "stimulus secretion-coupling electrode" that delivered high K + locally to depolarize the original or grafted cells under the recording CFE (Fig. 5A) . Perfusion of high K + for 5 s evoked a repeatable DA release in the intact dorsal striatum (Fig. 5A  and Fig. S8 ). The evoked DA overflow was diminished in the striatum on the lesioned side of PD-PBS rats; however, this was partially but significantly rescued in the cell-engrafted striatum in PD-DAn rats (Fig. 5 B and C) . Compared with the intact side, little DA release remained on the lesioned side of PD-PBS rats (Fig. 5C ) (intact side, 879.0 ± 181.6 pA; PD-PBS side, 24.4 ± 10.9 pA; P < 0.01), whereas the latter recovered to 152.4 ± 18.1 pA ( Fig. 5C ; P < 0.001) in PD-DAn rats, with kinetics similar to that in the intact side (Fig. 5D) . Because CFEs record the DA overflow at the millisecond scale, the kinetics of DA release (I amp rising phase) during stimulation and the immediately subsequent DA reuptake (I amp decay phase) can be clearly separated. The decay time constant (τ decay ) was similar in the cell-grafted and intact sides of the striatum (Fig. 5D) , suggesting that the DA reuptake in the pNSC-DAn-grafted striatum was rescued as well. In addition, although DA release was smaller in the grafted striatum than in the control side, the rise times and half-height durations (HHDs) were similar (Fig. 5D) . Together, the increased DA overflow signals in the grafted striatum were mainly due to DA release from grafted pNSC-DAns. In summary, by combining the two in vivo DA detection methods of microdialysis-based HPLC (for DA identification) and CFE amperometry (for real-time DA recording), we demonstrated that the transplanted ESC-derived DA-like neurons directly release DA in the PD striatum in vivo and thus reduce PD behaviors in rats (Fig. 6 ).
Discussion
One major finding in the present work was the rescue of DA release by grafted pNSC-DAns in the striatum in vivo. Cell-replacement therapy for PD using fetal midbrain cells has been attempted (2, (41) (42) (43) , but its application raises ethical issues. To overcome the main problem of cell sources for transplantation, extensive efforts have been made to generate DAns from renewable pluripotent stem cells , PD-PBS (n = 13 slices from 4 rats), and PD-DAn (n = 7 slices from 6 rats) rats (Student t test; ***P < 0.001, **P < 0.01). Left axis, I amp ; right axis, rescue by transplantation. (E) Statistics showing I amp differences between 1 and 2 sites (Student t test; **P <0.01; n = 7 slices from 6 rats). Left axis, I amp . 11, 17, 44, 45) . Since 2011, several groups including ours have developed a rapid and highly efficient method to differentiate human ESCs into renewable pNSCs, which subsequently produce massive numbers of DA-like neurons for PD treatment (12, 18, 19) . Importantly, striatal transplantation of pNSC-DAns significantly relieved the asymmetric rotation in a unilaterally damaged PD rat model (present work and see also refs. 12, 19) . In the present work, we demonstrated that pNSC-DAn transplantation rescued DA release in the PD striatum, as determined by both microdialysis-based HPLC (for unequivocal DA verification) and CFE amperometry (for high spatiotemporal resolution) recordings in vivo. The second major finding was determination of the cellular site of DA release in pNSC-DAn-transplanted striatal brain slices. Previous studies have shown that grafted cells can survive and reduce PD-like behaviors (6, 8-10, 13, 14) . In addition, DA release can be rescued in vivo by both mouse (33) and human (present work) ESC-derived cells in the grafted rat striatum. However, the critical question of whether the grafted cells release DA in vivo remained unanswered because the spatial (200 μm) and temporal (500 s) resolution of microdialysis-based HPLC was too low to distinguish grafted cells from residual cells within the implanted striatum. In contrast, DA recording by CFE amperometry has much higher spatial resolution (probe diameter, 7 μm versus 200 μm) temporal resolution (sample rate, 1 ms versus 10 min) (Fig. 6C) , making it possible to precisely record the location and kinetics of microregional DA release in striatal brain slices under a microscope. Strikingly, the restored DA release was limited to the grafted regions (Fig. 4) . Considering that the differentiated pNSCs were able to secrete DA in vitro and that the diminished TH staining in the lesioned striatum was rescued by the engraftment of pNSC-DAn and that most of the TH-positive cell bodies and neurites were also GFP-positive (Fig. 2  A-C and Fig. S4) , the increased DA level in the striatum is most likely directly released from the grafted pNSC-DAns.
With high-resolution CFE recordings, another finding was that pNSC-DAn rescued DA reuptake in slices from the grafted striatum and in vivo. Here, the kinetics of evoked DA release and reuptake in the grafted PD striatum were determined by the amperometric current with high temporal resolution, in which the rise time represents DA release and the decay time indicates DA reuptake (34, (46) (47) (48) . Interestingly, the depolarization-induced DA dynamics in the PD-grafted striatum were similar to those in the intact side, as evidenced by comparable rise times, HHDs, and decay times in the pNSC-DAn-grafted and intact sides of the striatum (Fig. 5) . Thus, the DA release-coupled clearance was rescued by the grafted pNSC-DAn as well.
Altogether, human ESC-derived pNSC-DA cells can be functionally integrated into the striatum. As summarized in Fig. 6 , the present study demonstrated that the rescued DA release and reuptake was most likely from grafted cells. Because human ESC-derived pNSCs, and probably also induced pluripotent stem cells from patients, have high efficacy for producing virtually infinite numbers of transplantable DAns, our work provides an in vivo mechanism for potential application of human ESCs in the treatment of PD.
Materials and Methods
Methods are described in detail in SI Materials and Methods. All animal procedures were approved by and performed according to the guidelines of the Peking University Animal Use and Care Committee and the Association for Assessment and Accreditation of Laboratory Animal Care.
Cell Culture and Differentiation of DAns. pNSCs were induced from human ESCs as previously described (18) . PD Model, Behavioral Testing, and Cell Transplantation. Adult male SpragueDawley rats (∼200 g) were microinjected with 6-OHDA into MFB to produce the PD model. The differentiated pNSC-DAns were microinjected into the ipsilateral striatum of the leisoned side of the PD rat, with PBS as the control. The rats were immunosuppressed by daily injection of cyclosporine A from 2 d before transplantation. Apomorphine-induced rotations were monitored every 4 wk after transplantation.
HPLC Detection of DA Release in Vitro and in Vivo. Microdialysis-based HPLC detection of the striatal DA and its metabolites were performed as described previously (32), with slight modifications. Cultured pNSC-DAns were incubated in the 3-mM K + -containing solution for 5 min, followed by 50 mM of the K + -containing solution for another 5 min, and the bath solution was collected for HPLC analysis.
Amperometric Recording in Vivo and in Striatal Slices. Electrochemical amperometric current (I amp ) was recorded in brain slices and in vivo using CFEs, as previously described (34, 37) . DA release was recorded as I amp (oxidization amperometric current) by a CFE (Ф7 μm) with a 200-μm sensor tip held at 780 mV. For in vivo recording of DA release in striatum, the anesthetized rat was stimulated and recorded by a laboratory-made puffer-coupled CFE (pcCFE), which is consisted of a combined CFE and delivery tube (Fig. 6B) . The pcCFE was placed in the striatum, and DA release was evoked by perfusion of 70 mM K + through the drug-delivery tube. DA recording of striatal slices was performed as previously described (49) . DA overflow was evoked by perfusion with 70 mM K + for 10 s and recorded by CFE. 
